SynthesisDiagnostic cytopathology2019
Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/IV thyroid nodules and inform therapeutic schedule.
Synthesis in Diagnostic cytopathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/IV thyroid nodules and inform therapeutic schedule.Diagnostic cytopathology · 2019Pooled it
- Encapsulated neoplasms of the thyroid gland.Virchows Archiv : an international journal of pathology · 2026Review
- Prevalence and predictors of malignancy in Bethesda III and IV thyroid nodules undergoing surgery.Frontiers in endocrinology · 2026Article
- Clinical Outcomes of Patients With Bethesda III or IV Cytology on Fine Needle Aspiration of Thyroid Nodules-A Retrospective Study.Endocrinology, diabetes & metabolism · 2025Article
- Utility of the Clinical and Radiological Features in the Management of Bethesda 3 and 4 Thyroid Nodules.Indian journal of surgical oncology · 2025Article
- Rates and Predictors of Malignancy in Bethesda III and IV Thyroid Nodules: A Prospective Study.Cureus · 2024Article
- Volume reduction rate of radiofrequency ablation in ≤ 2 cm Bethesda IV thyroid nodules.European radiology · 2024Observational
- Ultrasonographic predictors of thyroid cancer in Bethesda III and IV thyroid nodules.Frontiers in endocrinology · 2024Article
- Impact of ultrasound elastography in evaluating Bethesda category IV thyroid nodules with histopathological correlation.Frontiers in endocrinology · 2024Article
- Serum TSH as a predictor of malignancy in indeterminate thyroid nodules.Annals of the Royal College of Surgeons of England · 2022Article
- Article
- Analysis of Clinical-Radiological-Pathological Factors in FN/SFN Bethesda Category Thyroid Nodules, Contribution of FNAB Repeat, Single Center Experience.Sisli Etfal Hastanesi tip bulteni · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThis study was designed to explore whether ultrasound of thyroid nodules facilitates the interpretation of the malignant risk of Bethesda III/IV thyroid nodules to inform further therapies.
methodsWe reviewed patient records in which the results of ultrasound-guided fine-needle aspiration (US-FNA) were classified by the Bethesda III/IV in our institution between January 2016 and June 2018. Studies were retrieved from PubMed, Cochrane Central Register of Controlled Trials, ISI Web of Science, Science Direct, Wiley Online Library, EMBASE, China National Knowledge Infrastructure, WanFang, and Chinese VIP. The odds ratio (OR) was used to measure associations between risk factors and thyroid nodule malignancy.
resultsFifty-nine cases of Bethesda III/IV with corresponding surgeries were included, and the malignancy risk was 54.2%. Meta-analysis revealed irregular borders, solitary nodules, hypoechogenicity, microcalcifications, and being taller than wide, all of which increased the malignancy risk of thyroid nodules. Combined ORs for these factors were 4.08 (95% CI: 2.34-7.14, P < .001), 2.18 (95% CI: 1.39-3.42, P = .001), 2.02 (95% CI: 1.35-3.01, P = .001), 3.21 (95% CI: 2.26-4.56, P < .001), and 4.35 (95% CI: 3.07-6.15, P < .001), respectively.
conclusionAs the risk of malignancy for papillary thyroid carcinoma (PTC) is high, when any one of the five ultrasound features of malignancy were confirmed, repeated FNA is recommended to confirm PTC-type malignancy, even though nodules were Bethesda III/IV classification. However, repeated FNA should be avoided when none of these ultrasound features are identified because repeated FNA does not contribute to identifying non-PTC type malignancies, such as follicular thyroid carcinoma and poorly differentiated thyroid carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.